Ablynx up on MAA submission

Belgian drug developer Ablynx (Euronext Brussels: ABLX) was up by 1.5% at 12.20 euros ($13.07) as Monday’s trading neared its end after announcing news on caplacizumab, its anti-von Willebrand factor (vWF) nanobody for acquired thrombotic thrombocytopenic purpura (aTTP).

The company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of its drug in what is an ultra-rare, acute, life-threatening blood clotting disorder with a high unmet medical need.

"This is a very important moment in the development of Ablynx, as we prepare to commercialize our first product"